|
1
|
Ellison J, Caliva F, Damasceno P, Luks TL, LaFontaine M, Cluceru J, Kemisetti A, Li Y, Molinaro AM, Pedoia V, Villanueva-Meyer JE, Lupo JM. Improving the Generalizability of Deep Learning for T2-Lesion Segmentation of Gliomas in the Post-Treatment Setting. Bioengineering (Basel) 2024; 11:497. [PMID: 38790363 PMCID: PMC11117752 DOI: 10.3390/bioengineering11050497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2024] [Revised: 04/24/2024] [Accepted: 05/07/2024] [Indexed: 05/26/2024] Open
Abstract
Although fully automated volumetric approaches for monitoring brain tumor response have many advantages, most available deep learning models are optimized for highly curated, multi-contrast MRI from newly diagnosed gliomas, which are not representative of post-treatment cases in the clinic. Improving segmentation for treated patients is critical to accurately tracking changes in response to therapy. We investigated mixing data from newly diagnosed (n = 208) and treated (n = 221) gliomas in training, applying transfer learning (TL) from pre- to post-treatment imaging domains, and incorporating spatial regularization for T2-lesion segmentation using only T2 FLAIR images as input to improve generalization post-treatment. These approaches were evaluated on 24 patients suspected of progression who had received prior treatment. Including 26% of treated patients in training improved performance by 13.9%, and including more treated and untreated patients resulted in minimal changes. Fine-tuning with treated glioma improved sensitivity compared to data mixing by 2.5% (p < 0.05), and spatial regularization further improved performance when used with TL by 95th HD, Dice, and sensitivity (6.8%, 0.8%, 2.2%; p < 0.05). While training with ≥60 treated patients yielded the majority of performance gain, TL and spatial regularization further improved T2-lesion segmentation to treated gliomas using a single MR contrast and minimal processing, demonstrating clinical utility in response assessment.
Collapse
Affiliation(s)
- Jacob Ellison
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
- Center for Intelligent Imaging, UCSF, San Francisco, CA 94143, USA
- UCSF/UC Berkeley Graduate Program in Bioengineering, San Francisco, CA 94143, USA
| | - Francesco Caliva
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
- Center for Intelligent Imaging, UCSF, San Francisco, CA 94143, USA
| | - Pablo Damasceno
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
- Center for Intelligent Imaging, UCSF, San Francisco, CA 94143, USA
| | - Tracy L. Luks
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
| | - Marisa LaFontaine
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
| | - Julia Cluceru
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
- Center for Intelligent Imaging, UCSF, San Francisco, CA 94143, USA
| | - Anil Kemisetti
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
| | - Yan Li
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
- Center for Intelligent Imaging, UCSF, San Francisco, CA 94143, USA
| | | | - Valentina Pedoia
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
- Center for Intelligent Imaging, UCSF, San Francisco, CA 94143, USA
- UCSF/UC Berkeley Graduate Program in Bioengineering, San Francisco, CA 94143, USA
| | - Javier E. Villanueva-Meyer
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
- Center for Intelligent Imaging, UCSF, San Francisco, CA 94143, USA
| | - Janine M. Lupo
- Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94143, USA; (J.E.); (F.C.); (P.D.); (T.L.L.); (M.L.); (J.C.); (A.K.); (Y.L.); (V.P.); (J.E.V.-M.)
- Center for Intelligent Imaging, UCSF, San Francisco, CA 94143, USA
- UCSF/UC Berkeley Graduate Program in Bioengineering, San Francisco, CA 94143, USA
| |
Collapse
|
|
2
|
Liu J, Jakary A, Villanueva-Meyer JE, Butowski NA, Saloner D, Clarke JL, Taylor JW, Oberheim Bush NA, Chang SM, Xu D, Lupo JM. Automatic Brain Tissue and Lesion Segmentation and Multi-Parametric Mapping of Contrast-Enhancing Gliomas without the Injection of Contrast Agents: A Preliminary Study. Cancers (Basel) 2024; 16:1524. [PMID: 38672606 PMCID: PMC11049314 DOI: 10.3390/cancers16081524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2024] [Revised: 04/08/2024] [Accepted: 04/15/2024] [Indexed: 04/28/2024] Open
Abstract
This study aimed to develop a rapid, 1 mm3 isotropic resolution, whole-brain MRI technique for automatic lesion segmentation and multi-parametric mapping without using contrast by continuously applying balanced steady-state free precession with inversion pulses throughout incomplete inversion recovery in a single 6 min scan. Modified k-means clustering was performed for automatic brain tissue and lesion segmentation using distinct signal evolutions that contained mixed T1/T2/magnetization transfer properties. Multi-compartment modeling was used to derive quantitative multi-parametric maps for tissue characterization. Fourteen patients with contrast-enhancing gliomas were scanned with this sequence prior to the injection of a contrast agent, and their segmented lesions were compared to conventionally defined manual segmentations of T2-hyperintense and contrast-enhancing lesions. Simultaneous T1, T2, and macromolecular proton fraction maps were generated and compared to conventional 2D T1 and T2 mapping and myelination water fraction mapping acquired with MAGiC. The lesion volumes defined with the new method were comparable to the manual segmentations (r = 0.70, p < 0.01; t-test p > 0.05). The T1, T2, and macromolecular proton fraction mapping values of the whole brain were comparable to the reference values and could distinguish different brain tissues and lesion types (p < 0.05), including infiltrating tumor regions within the T2-lesion. Highly efficient, whole-brain, multi-contrast imaging facilitated automatic lesion segmentation and quantitative multi-parametric mapping without contrast, highlighting its potential value in the clinic when gadolinium is contraindicated.
Collapse
Affiliation(s)
- Jing Liu
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA; (A.J.); (D.X.)
| | - Angela Jakary
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA; (A.J.); (D.X.)
| | - Javier E. Villanueva-Meyer
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA; (A.J.); (D.X.)
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA; (N.A.B.); (J.L.C.); (S.M.C.)
| | - Nicholas A. Butowski
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA; (N.A.B.); (J.L.C.); (S.M.C.)
| | - David Saloner
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA; (A.J.); (D.X.)
- Radiology Service, VA Medical Center, San Francisco, CA 94121, USA
| | - Jennifer L. Clarke
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA; (N.A.B.); (J.L.C.); (S.M.C.)
- Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA
| | - Jennie W. Taylor
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA; (N.A.B.); (J.L.C.); (S.M.C.)
- Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA
| | - Nancy Ann Oberheim Bush
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA; (N.A.B.); (J.L.C.); (S.M.C.)
- Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA
| | - Susan M. Chang
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA; (N.A.B.); (J.L.C.); (S.M.C.)
| | - Duan Xu
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA; (A.J.); (D.X.)
- UCSF/UC Berkeley Graduate Program in Bioengineering, University of California San Francisco and Berkeley, San Francisco, CA 94143, USA
| | - Janine M. Lupo
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA; (A.J.); (D.X.)
- UCSF/UC Berkeley Graduate Program in Bioengineering, University of California San Francisco and Berkeley, San Francisco, CA 94143, USA
| |
Collapse
|
|
3
|
Wiestler B, Bison B, Behrens L, Tüchert S, Metz M, Griessmair M, Jakob M, Schlegel PG, Binder V, von Luettichau I, Metzler M, Johann P, Hau P, Frühwald M. Human-Level Differentiation of Medulloblastoma from Pilocytic Astrocytoma: A Real-World Multicenter Pilot Study. Cancers (Basel) 2024; 16:1474. [PMID: 38672556 PMCID: PMC11048511 DOI: 10.3390/cancers16081474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Revised: 04/05/2024] [Accepted: 04/08/2024] [Indexed: 04/28/2024] Open
Abstract
Medulloblastoma and pilocytic astrocytoma are the two most common pediatric brain tumors with overlapping imaging features. In this proof-of-concept study, we investigated using a deep learning classifier trained on a multicenter data set to differentiate these tumor types. We developed a patch-based 3D-DenseNet classifier, utilizing automated tumor segmentation. Given the heterogeneity of imaging data (and available sequences), we used all individually available preoperative imaging sequences to make the model robust to varying input. We compared the classifier to diagnostic assessments by five readers with varying experience in pediatric brain tumors. Overall, we included 195 preoperative MRIs from children with medulloblastoma (n = 69) or pilocytic astrocytoma (n = 126) across six university hospitals. In the 64-patient test set, the DenseNet classifier achieved a high AUC of 0.986, correctly predicting 62/64 (97%) diagnoses. It misclassified one case of each tumor type. Human reader accuracy ranged from 100% (expert neuroradiologist) to 80% (resident). The classifier performed significantly better than relatively inexperienced readers (p < 0.05) and was on par with pediatric neuro-oncology experts. Our proof-of-concept study demonstrates a deep learning model based on automated tumor segmentation that can reliably preoperatively differentiate between medulloblastoma and pilocytic astrocytoma, even in heterogeneous data.
Collapse
Affiliation(s)
- Benedikt Wiestler
- Department of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany (M.G.)
- TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675 Munich, Germany
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
| | - Brigitte Bison
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- KIONET, Kinderonkologisches Netzwerk Bayern
- Diagnostic and Interventional Neuroradiology, Faculty of Medicine, University Hospital Augsburg, 86156 Augsburg, Germany; (B.B.); (L.B.)
- Neuroradiological Reference Center for the Pediatric Brain Tumor (HIT) Studies of the German Society of Pediatric Oncology and Hematology, Faculty of Medicine, University Hospital Augsburg, 86156 Augsburg, Germany
| | - Lars Behrens
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- KIONET, Kinderonkologisches Netzwerk Bayern
- Diagnostic and Interventional Neuroradiology, Faculty of Medicine, University Hospital Augsburg, 86156 Augsburg, Germany; (B.B.); (L.B.)
- Neuroradiological Reference Center for the Pediatric Brain Tumor (HIT) Studies of the German Society of Pediatric Oncology and Hematology, Faculty of Medicine, University Hospital Augsburg, 86156 Augsburg, Germany
| | - Stefanie Tüchert
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- Department of Diagnostic and Interventional Radiology, University Hospital Augsburg, 86156 Augsburg, Germany
| | - Marie Metz
- Department of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany (M.G.)
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
| | - Michael Griessmair
- Department of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany (M.G.)
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
| | - Marcus Jakob
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- KIONET, Kinderonkologisches Netzwerk Bayern
- Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, 93053 Regensburg, Germany;
| | - Paul-Gerhardt Schlegel
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- KIONET, Kinderonkologisches Netzwerk Bayern
- Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Children’s Hospital Würzburg, 97080 Würzburg, Germany;
| | - Vera Binder
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- KIONET, Kinderonkologisches Netzwerk Bayern
- Department of Pediatrics, Dr. Von Hauner Children’s Hospital, University Hospital, LMU Munich, 80539 Munich, Germany;
| | - Irene von Luettichau
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- KIONET, Kinderonkologisches Netzwerk Bayern
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kinderklinik München Schwabing, Children’s Cancer Research Center, TUM School of Medicine and Health, Technical University of Munich, 80333 Munich, Germany;
| | - Markus Metzler
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- KIONET, Kinderonkologisches Netzwerk Bayern
- Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany;
| | - Pascal Johann
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- KIONET, Kinderonkologisches Netzwerk Bayern
- Swabian Children’s Cancer Center, Pediatrics and Adolescent Medicine, University Hospital Augsburg, 86156 Augsburg, Germany; (P.J.); (M.F.)
| | - Peter Hau
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, 93053 Regensburg, Germany;
| | - Michael Frühwald
- Study Groups on CNS Tumors Within the Bavarian Cancer Research Center (BZKF)
- KIONET, Kinderonkologisches Netzwerk Bayern
- Swabian Children’s Cancer Center, Pediatrics and Adolescent Medicine, University Hospital Augsburg, 86156 Augsburg, Germany; (P.J.); (M.F.)
| |
Collapse
|
|
4
|
Park YW, Park JE, Ahn SS, Han K, Kim N, Oh JY, Lee DH, Won SY, Shin I, Kim HS, Lee SK. Deep learning-based metastasis detection in patients with lung cancer to enhance reproducibility and reduce workload in brain metastasis screening with MRI: a multi-center study. Cancer Imaging 2024; 24:32. [PMID: 38429843 PMCID: PMC10905821 DOI: 10.1186/s40644-024-00669-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Accepted: 01/29/2024] [Indexed: 03/03/2024] Open
Abstract
OBJECTIVES To assess whether a deep learning-based system (DLS) with black-blood imaging for brain metastasis (BM) improves the diagnostic workflow in a multi-center setting. MATERIALS AND METHODS In this retrospective study, a DLS was developed in 101 patients and validated on 264 consecutive patients (with lung cancer) having newly developed BM from two tertiary university hospitals, which performed black-blood imaging between January 2020 and April 2021. Four neuroradiologists independently evaluated BM either with segmented masks and BM counts provided (with DLS) or not provided (without DLS) on a clinical trial imaging management system (CTIMS). To assess reading reproducibility, BM count agreement between the readers and the reference standard were calculated using limits of agreement (LoA). Readers' workload was assessed with reading time, which was automatically measured on CTIMS, and were compared between with and without DLS using linear mixed models considering the imaging center. RESULTS In the validation cohort, the detection sensitivity and positive predictive value of the DLS were 90.2% (95% confidence interval [CI]: 88.1-92.2) and 88.2% (95% CI: 85.7-90.4), respectively. The difference between the readers and the reference counts was larger without DLS (LoA: -0.281, 95% CI: -2.888, 2.325) than with DLS (LoA: -0.163, 95% CI: -2.692, 2.367). The reading time was reduced from mean 66.9 s (interquartile range: 43.2-90.6) to 57.3 s (interquartile range: 33.6-81.0) (P <.001) in the with DLS group, regardless of the imaging center. CONCLUSION Deep learning-based BM detection and counting with black-blood imaging improved reproducibility and reduced reading time, on multi-center validation.
Collapse
Affiliation(s)
- Yae Won Park
- Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Korea
| | - Ji Eun Park
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 43 Olympic-ro 88, Songpa-Gu, 05505, Seoul, Korea.
| | - Sung Soo Ahn
- Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Korea.
| | - Kyunghwa Han
- Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Korea
| | | | - Joo Young Oh
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 43 Olympic-ro 88, Songpa-Gu, 05505, Seoul, Korea
| | - Da Hyun Lee
- Department of Radiology, Ajou University Medical Center, Suwon, Korea
| | - So Yeon Won
- Department of Radiology, Samsung Seoul Hospital, Seoul, Korea
| | - Ilah Shin
- Department of Radiology, The Catholic University of Korea, Seoul St. Mary's hospital, Seoul, Korea
| | - Ho Sung Kim
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 43 Olympic-ro 88, Songpa-Gu, 05505, Seoul, Korea
| | - Seung-Koo Lee
- Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Korea
| |
Collapse
|
|
5
|
Heuer S, Burghaus I, Gose M, Kessler T, Sahm F, Vollmuth P, Venkataramani V, Hoffmann D, Schlesner M, Ratliff M, Hopf C, Herrlinger U, Ricklefs F, Bendszus M, Krieg SM, Wick A, Wick W, Winkler F. PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma. BMC Cancer 2024; 24:135. [PMID: 38279087 PMCID: PMC10811925 DOI: 10.1186/s12885-024-11846-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Accepted: 01/04/2024] [Indexed: 01/28/2024] Open
Abstract
BACKGROUND Glioblastoma is the most frequent and a particularly malignant primary brain tumor with no efficacy-proven standard therapy for recurrence. It has recently been discovered that excitatory synapses of the AMPA-receptor subtype form between non-malignant brain neurons and tumor cells. This neuron-tumor network connectivity contributed to glioma progression and could be efficiently targeted with the EMA/FDA approved antiepileptic AMPA receptor inhibitor perampanel in preclinical studies. The PerSurge trial was designed to test the clinical potential of perampanel to reduce tumor cell network connectivity and tumor growth with an extended window-of-opportunity concept. METHODS PerSurge is a phase IIa clinical and translational treatment study around surgical resection of progressive or recurrent glioblastoma. In this multicenter, 2-arm parallel-group, double-blind superiority trial, patients are 1:1 randomized to either receive placebo or perampanel (n = 66 in total). It consists of a treatment and observation period of 60 days per patient, starting 30 days before a planned surgical resection, which itself is not part of the study interventions. Only patients with an expected safe waiting interval are included, and a safety MRI is performed. Tumor cell network connectivity from resected tumor tissue on single cell transcriptome level as well as AI-based assessment of tumor growth dynamics in T2/FLAIR MRI scans before resection will be analyzed as the co-primary endpoints. Secondary endpoints will include further imaging parameters such as pre- and postsurgical contrast enhanced MRI scans, postsurgical T2/FLAIR MRI scans, quality of life, cognitive testing, overall and progression-free survival as well as frequency of epileptic seizures. Further translational research will focus on additional biological aspects of neuron-tumor connectivity. DISCUSSION This trial is set up to assess first indications of clinical efficacy and tolerability of perampanel in recurrent glioblastoma, a repurposed drug which inhibits neuron-glioma synapses and thereby glioblastoma growth in preclinical models. If perampanel proved to be successful in the clinical setting, it would provide the first evidence that interference with neuron-cancer interactions may indeed lead to a benefit for patients, which would lay the foundation for a larger confirmatory trial in the future. TRIAL REGISTRATION EU-CT number: 2023-503938-52-00 30.11.2023.
Collapse
Affiliation(s)
- Sophie Heuer
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| | - Ina Burghaus
- Coordination Centre for Clinical Trials (KKS) Heidelberg, 69120, Heidelberg, Germany
| | - Maria Gose
- Coordination Centre for Clinical Trials (KKS) Heidelberg, 69120, Heidelberg, Germany
| | - Tobias Kessler
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| | - Felix Sahm
- Department of Neuropathology, University Hospital Heidelberg, INF 224, 69120, Heidelberg, Germany
- CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), Geman Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Philipp Vollmuth
- Department of Neuroradiology, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany
| | - Varun Venkataramani
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
- Department of Functional Neuroanatomy, Institute for Anatomy and Cell Biology, Heidelberg University, Heidelberg, Germany
| | - Dirk Hoffmann
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| | - Matthias Schlesner
- German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
- Biomedical Informatics, Data Mining and Data Analytics, University of Augsburg, Augsburg, Germany
| | - Miriam Ratliff
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
- Neurosurgery Clinic, University Hospital Mannheim, 68167, Mannheim, Germany
| | - Carsten Hopf
- Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack Str. 10, 68163, Mannheim, Germany
- Medical Faculty, Heidelberg University, Heidelberg, Germany
- Mannheim Center for Translational Neuroscience (MCTN), Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
| | - Ulrich Herrlinger
- Division of Clinical Neurooncology, Department of Neurology and Centre of Integrated Oncology, University Hospital Bonn, Bonn, Germany
| | - Franz Ricklefs
- Department of Neurosurgery, University Hospital Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Martin Bendszus
- Department of Neuroradiology, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany
| | - Sandro M Krieg
- Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
| | - Antje Wick
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany
| | - Wolfgang Wick
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| | - Frank Winkler
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
| |
Collapse
|
|
6
|
von Reppert M, Ramakrishnan D, Brüningk SC, Memon F, Abi Fadel S, Maleki N, Bahar R, Avesta AE, Jekel L, Sala M, Lost J, Tillmanns N, Kaur M, Aneja S, Fathi Kazerooni A, Nabavizadeh A, Lin M, Hoffmann KT, Bousabarah K, Swanson KR, Haas-Kogan D, Mueller S, Aboian MS. Comparison of volumetric and 2D-based response methods in the PNOC-001 pediatric low-grade glioma clinical trial. Neurooncol Adv 2024; 6:vdad172. [PMID: 38221978 PMCID: PMC10785766 DOI: 10.1093/noajnl/vdad172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2024] Open
Abstract
Background Although response in pediatric low-grade glioma (pLGG) includes volumetric assessment, more simplified 2D-based methods are often used in clinical trials. The study's purpose was to compare volumetric to 2D methods. Methods An expert neuroradiologist performed solid and whole tumor (including cyst and edema) volumetric measurements on MR images using a PACS-based manual segmentation tool in 43 pLGG participants (213 total follow-up images) from the Pacific Pediatric Neuro-Oncology Consortium (PNOC-001) trial. Classification based on changes in volumetric and 2D measurements of solid tumor were compared to neuroradiologist visual response assessment using the Brain Tumor Reporting and Data System (BT-RADS) criteria for a subset of 65 images using receiver operating characteristic (ROC) analysis. Longitudinal modeling of solid tumor volume was used to predict BT-RADS classification in 54 of the 65 images. Results There was a significant difference in ROC area under the curve between 3D solid tumor volume and 2D area (0.96 vs 0.78, P = .005) and between 3D solid and 3D whole volume (0.96 vs 0.84, P = .006) when classifying BT-RADS progressive disease (PD). Thresholds of 15-25% increase in 3D solid tumor volume had an 80% sensitivity in classifying BT-RADS PD included in their 95% confidence intervals. The longitudinal model of solid volume response had a sensitivity of 82% and a positive predictive value of 67% for detecting BT-RADS PD. Conclusions Volumetric analysis of solid tumor was significantly better than 2D measurements in classifying tumor progression as determined by BT-RADS criteria and will enable more comprehensive clinical management.
Collapse
Affiliation(s)
- Marc von Reppert
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
- Department of Neuroradiology, Leipzig University Hospital, Leipzig, Germany
| | - Divya Ramakrishnan
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Sarah C Brüningk
- Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland
- Swiss Institute for Bioinformatics (SIB), Lausanne, Switzerland
| | - Fatima Memon
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Sandra Abi Fadel
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Nazanin Maleki
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Ryan Bahar
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Arman E Avesta
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA
- Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, USA
- Department of Neuroradiology, Harvard Medical School—Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Leon Jekel
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
- University of Duisburg-Essen, Essen, Germany
| | - Matthew Sala
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
- Tulane School of Medicine, New Orleans, Louisiana, USA
| | - Jan Lost
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
- Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
| | - Niklas Tillmanns
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
- Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
| | - Manpreet Kaur
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
- Ludwig Maximilian University, Munich, Germany
| | - Sanjay Aneja
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA
- Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, USA
| | - Anahita Fathi Kazerooni
- Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Ali Nabavizadeh
- Center for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
| | - MingDe Lin
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
- Visage Imaging, Inc., San Diego, California, USA
| | | | | | - Kristin R Swanson
- Mathematical Neuro-Oncology Lab, Department of Neurological Surgery, Mayo Clinic, Phoenix, Arizona, USA
| | - Daphne Haas-Kogan
- Department of Radiation Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Sabine Mueller
- Department of Neurology, Neurosurgery, and Pediatrics, UCSF, San Francisco, California, USA
- Children’s University Hospital Zürich, Zürich, Switzerland
| | - Mariam S Aboian
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| |
Collapse
|
|
7
|
Hoebel KV, Bridge CP, Ahmed S, Akintola O, Chung C, Huang RY, Johnson JM, Kim A, Ly KI, Chang K, Patel J, Pinho M, Batchelor TT, Rosen BR, Gerstner ER, Kalpathy-Cramer J. Expert-centered Evaluation of Deep Learning Algorithms for Brain Tumor Segmentation. Radiol Artif Intell 2024; 6:e220231. [PMID: 38197800 PMCID: PMC10831514 DOI: 10.1148/ryai.220231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 09/13/2023] [Accepted: 11/01/2023] [Indexed: 01/11/2024]
Abstract
Purpose To present results from a literature survey on practices in deep learning segmentation algorithm evaluation and perform a study on expert quality perception of brain tumor segmentation. Materials and Methods A total of 180 articles reporting on brain tumor segmentation algorithms were surveyed for the reported quality evaluation. Additionally, ratings of segmentation quality on a four-point scale were collected from medical professionals for 60 brain tumor segmentation cases. Results Of the surveyed articles, Dice score, sensitivity, and Hausdorff distance were the most popular metrics to report segmentation performance. Notably, only 2.8% of the articles included clinical experts' evaluation of segmentation quality. The experimental results revealed a low interrater agreement (Krippendorff α, 0.34) in experts' segmentation quality perception. Furthermore, the correlations between the ratings and commonly used quantitative quality metrics were low (Kendall tau between Dice score and mean rating, 0.23; Kendall tau between Hausdorff distance and mean rating, 0.51), with large variability among the experts. Conclusion The results demonstrate that quality ratings are prone to variability due to the ambiguity of tumor boundaries and individual perceptual differences, and existing metrics do not capture the clinical perception of segmentation quality. Keywords: Brain Tumor Segmentation, Deep Learning Algorithms, Glioblastoma, Cancer, Machine Learning Clinical trial registration nos. NCT00756106 and NCT00662506 Supplemental material is available for this article. © RSNA, 2023.
Collapse
Affiliation(s)
- Katharina V. Hoebel
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Christopher P. Bridge
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Sara Ahmed
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Oluwatosin Akintola
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Caroline Chung
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Raymond Y. Huang
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Jason M. Johnson
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Albert Kim
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - K. Ina Ly
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Ken Chang
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Jay Patel
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Marco Pinho
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Tracy T. Batchelor
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Bruce R. Rosen
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Elizabeth R. Gerstner
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| | - Jayashree Kalpathy-Cramer
- From the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (K.V.H., C.P.B., A.K., K.I.L., K.C., J.P., B.R.R., E.R.G., J.K.C.), and Stephen E. and Catherine Pappas Center for Neuro-Oncology (O.A., A.K., K.I.L., E.R.G.), Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass (K.V.H., K.C., J.P.); MGH and BWH Center for Clinical Data Science, Boston, Mass (C.P.B., J.K.C.); Department of Radiation Oncology, Division of Radiation Oncology (S.A., C.C.); Department of Diagnostic Radiology, Division of Diagnostic Imaging (C.C.), and Department of Neuroradiology (J.M.J.), Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex; Departments of Radiology (R.Y.H.) and Neurology (T.T.B.), Brigham and Women’s Hospital, Boston, Mass; Department of Radiology and Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Tex (M.P.); and Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colo (J.K.C.)
| |
Collapse
|
|
8
|
Pikūnienė I, Strakšytė V, Basevičius A, Žilinskas J, Ambrazienė R, Jančiauskienė R, Saladžinskas Ž. Prognostic Value of Tumor Volume, Tumor Volume Reduction Rate and Magnetic Resonance Tumor Regression Grade in Rectal Cancer. MEDICINA (KAUNAS, LITHUANIA) 2023; 59:2194. [PMID: 38138297 PMCID: PMC10744935 DOI: 10.3390/medicina59122194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2023] [Revised: 12/10/2023] [Accepted: 12/15/2023] [Indexed: 12/24/2023]
Abstract
Background and Objectives: Rectal cancer poses significant treatment challenges, especially in advanced stages. Radiologic assessment, particularly with MRI, is critical for surgeons and oncologists to understand tumor dynamics and tailor treatment strategies to improve patient outcomes. The purpose of this study was to correlate MRI-based tumor volumetric and tumor regression grade analysis in patients with advanced rectal cancer, assessing the impact of preoperative chemotherapy (CT) alone or chemoradiotherapy (CRT) on surgical technique choices. Materials and Methods: Between 2015 and 2022, a prospective study was enrolled, including a cohort of 89 patients diagnosed with rectal cancer at stage II or III. The participants were divided into two distinct therapy groups, ensuring an equal distribution with a ratio of 1:1. The initial group was treated with the contemporary preoperative chemotherapy protocol FOLFOX4. In contrast, the alternative group received conventional preoperative chemoradiotherapy. Before surgery, each patient underwent a rectal MRI scan at 1.5 T, including T2-weighted and diffusion-weighted imaging (DWI) sequences. Results: The CT group showed a 36.52% tumor volume reduction rate (TVRR), and the CRT group showed 54.87%, with varying magnetic resonance and pathological tumor regression grades (mrTRG and pTRG). Analysis revealed a significant interaction between mrTRG and tumor volumetrics (volume and VRR) in both groups, especially CRT, underscoring the complexity of tumor response. Both treatment groups had similar initial tumor volumes, with CRT displaying a higher TVRR, particularly in higher pathological TRG (3/4) cases. This interaction and the strong correlation between mrTRG and pTRG suggest mrTRG's role as a non-invasive predictor for treatment response, highlighting the need for personalized treatment plans. Conclusions: Rectal tumor volume, volume reduction rate, and mrTRG are not just abstract measures; they are concrete indicators that have a direct and practical impact on surgical decision-making, planning, and prognosis, ultimately influencing the quality of care and life expectancy of patients with rectal cancer.
Collapse
Affiliation(s)
- Ingrida Pikūnienė
- Department of Radiology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161 Kaunas, Lithuania (A.B.)
| | - Vestina Strakšytė
- Department of Radiology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161 Kaunas, Lithuania (A.B.)
| | - Algidas Basevičius
- Department of Radiology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161 Kaunas, Lithuania (A.B.)
| | - Justas Žilinskas
- Department of Surgery, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161 Kaunas, Lithuania; (J.Ž.); (Ž.S.)
| | - Rita Ambrazienė
- The Institute of Oncology of the Faculty of Medicine, Lituanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (R.A.)
| | - Rasa Jančiauskienė
- The Institute of Oncology of the Faculty of Medicine, Lituanian University of Health Sciences, LT-50161 Kaunas, Lithuania; (R.A.)
| | - Žilvinas Saladžinskas
- Department of Surgery, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161 Kaunas, Lithuania; (J.Ž.); (Ž.S.)
| |
Collapse
|
|
9
|
Young JS, Morshed RA, Hervey-Jumper SL, Berger MS. The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions. Neuro Oncol 2023; 25:2117-2133. [PMID: 37499054 PMCID: PMC10708937 DOI: 10.1093/neuonc/noad133] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Indexed: 07/29/2023] Open
Abstract
After recent updates to the World Health Organization pathological criteria for diagnosing and grading diffuse gliomas, all major North American and European neuro-oncology societies recommend a maximal safe resection as the initial management of a diffuse glioma. For neurosurgeons to achieve this goal, the surgical plan for both low- and high-grade gliomas should be to perform a supramaximal resection when feasible based on preoperative imaging and the patient's performance status, utilizing every intraoperative adjunct to minimize postoperative neurological deficits. While the surgical approach and technique can vary, every effort must be taken to identify and preserve functional cortical and subcortical regions. In this summary statement on the current state of the field, we describe the tools and technologies that facilitate the safe removal of diffuse gliomas and highlight intraoperative and postoperative management strategies to minimize complications for these patients. Moreover, we discuss how surgical resections can go beyond cytoreduction by facilitating biological discoveries and improving the local delivery of adjuvant chemo- and radiotherapies.
Collapse
Affiliation(s)
- Jacob S Young
- Department of Neurological Surgery, University of California, San Francisco, USA
| | - Ramin A Morshed
- Department of Neurological Surgery, University of California, San Francisco, USA
| | | | - Mitchel S Berger
- Department of Neurological Surgery, University of California, San Francisco, USA
| |
Collapse
|
|
10
|
Li HB, Conte GM, Anwar SM, Kofler F, Ezhov I, van Leemput K, Piraud M, Diaz M, Cole B, Calabrese E, Rudie J, Meissen F, Adewole M, Janas A, Kazerooni AF, LaBella D, Moawad AW, Farahani K, Eddy J, Bergquist T, Chung V, Shinohara RT, Dako F, Wiggins W, Reitman Z, Wang C, Liu X, Jiang Z, Familiar A, Johanson E, Meier Z, Davatzikos C, Freymann J, Kirby J, Bilello M, Fathallah-Shaykh HM, Wiest R, Kirschke J, Colen RR, Kotrotsou A, Lamontagne P, Marcus D, Milchenko M, Nazeri A, Weber MA, Mahajan A, Mohan S, Mongan J, Hess C, Cha S, Villanueva-Meyer J, Colak E, Crivellaro P, Jakab A, Albrecht J, Anazodo U, Aboian M, Yu T, Chung V, Bergquist T, Eddy J, Albrecht J, Baid U, Bakas S, Linguraru MG, Menze B, Iglesias JE, Wiestler B. The Brain Tumor Segmentation (BraTS) Challenge 2023: Brain MR Image Synthesis for Tumor Segmentation (BraSyn). ARXIV 2023:arXiv:2305.09011v5. [PMID: 37608932 PMCID: PMC10441440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 08/24/2023]
Abstract
Automated brain tumor segmentation methods have become well-established and reached performance levels offering clear clinical utility. These methods typically rely on four input magnetic resonance imaging (MRI) modalities: T1-weighted images with and without contrast enhancement, T2-weighted images, and FLAIR images. However, some sequences are often missing in clinical practice due to time constraints or image artifacts, such as patient motion. Consequently, the ability to substitute missing modalities and gain segmentation performance is highly desirable and necessary for the broader adoption of these algorithms in the clinical routine. In this work, we present the establishment of the Brain MR Image Synthesis Benchmark (BraSyn) in conjunction with the Medical Image Computing and Computer-Assisted Intervention (MICCAI) 2023. The primary objective of this challenge is to evaluate image synthesis methods that can realistically generate missing MRI modalities when multiple available images are provided. The ultimate aim is to facilitate automated brain tumor segmentation pipelines. The image dataset used in the benchmark is diverse and multi-modal, created through collaboration with various hospitals and research institutions.
Collapse
Affiliation(s)
- Hongwei Bran Li
- University of Zurich, Switzerland
- Department of Informatics, Technical University Munich, Germany
- Klinikum rechts der Isar, Technical University of Munich, Germany
| | | | - Syed Muhammad Anwar
- Children's National Hospital, Washington DC, USA
- George Washington University, Washington DC, USA
| | - Florian Kofler
- Helmholtz AI, Helmholtz Munich, Germany
- Department of Informatics, Technical University Munich, Germany
- TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Germany
- Department of Diagnostic and Interventional Neuroradiology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
| | - Ivan Ezhov
- Department of Informatics, Technical University Munich, Germany
| | | | | | | | | | - Evan Calabrese
- Duke University Medical Center, Department of Radiology, USA
- University of California San Francisco, CA, USA
| | - Jeff Rudie
- University of California San Francisco, CA, USA
| | - Felix Meissen
- Department of Informatics, Technical University Munich, Germany
| | - Maruf Adewole
- Medical Artificial Intelligence (MAI) Lab, Crestview Radiology, Lagos, Nigeria
| | | | - Anahita Fathi Kazerooni
- Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
- Center for AI and Data Science for Integrated Diagnostics (AI2D) I& Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
| | - Dominic LaBella
- Duke University Medical Center, Department of Radiation Oncology, USA
| | | | - Keyvan Farahani
- Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA
| | | | | | | | - Russell Takeshi Shinohara
- Center for AI and Data Science for Integrated Diagnostics (AI2D) I& Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, USA
| | - Farouk Dako
- Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Walter Wiggins
- Duke University Medical Center, Department of Radiology, USA
| | - Zachary Reitman
- Duke University Medical Center, Department of Radiation Oncology, USA
| | - Chunhao Wang
- Duke University Medical Center, Department of Radiation Oncology, USA
| | - Xinyang Liu
- Children's National Hospital, Washington DC, USA
- George Washington University, Washington DC, USA
| | - Zhifan Jiang
- Children's National Hospital, Washington DC, USA
- George Washington University, Washington DC, USA
| | - Ariana Familiar
- Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
| | - Elaine Johanson
- PrecisionFDA, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | | | - Christos Davatzikos
- Center for AI and Data Science for Integrated Diagnostics (AI2D) I& Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - John Freymann
- Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA
- Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA
| | - Justin Kirby
- Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA
- Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA
| | - Michel Bilello
- Center for AI and Data Science for Integrated Diagnostics (AI2D) I& Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | | | - Roland Wiest
- Institute for Surgical Technology and Biomechanics, University of Bern, Bern, Switzerland
- Support Centre for Advanced Neuroimaging Inselspital, Institute for Diagnostic and Interventional Neuroradiology, Bern University Hospital, Bern, Switzerland
| | - Jan Kirschke
- Department of Neuroradiology, Technical University of Munich, Munich, Germany
| | - Rivka R Colen
- University of Pittsburgh Medical Center, PA, USA
- Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Aikaterini Kotrotsou
- Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Daniel Marcus
- Neuroimaging Informatics and Analysis Center, Washington University, St. Louis, MO, USA
- Department of Radiology, Washington University, St. Louis, MO, USA
| | - Mikhail Milchenko
- Neuroimaging Informatics and Analysis Center, Washington University, St. Louis, MO, USA
- Department of Radiology, Washington University, St. Louis, MO, USA
| | - Arash Nazeri
- Department of Radiology, Washington University, St. Louis, MO, USA
| | - Marc-André Weber
- Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, University Medical Center Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany
| | - Abhishek Mahajan
- Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - Suyash Mohan
- Center for AI and Data Science for Integrated Diagnostics (AI2D) I& Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - John Mongan
- University of California San Francisco, CA, USA
| | | | - Soonmee Cha
- University of California San Francisco, CA, USA
| | | | | | | | | | | | - Udunna Anazodo
- Montreal Neurological Institute (MNI), McGill University, Montreal, QC, Canada
| | | | - Thomas Yu
- Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School, USA
| | | | | | | | | | - Ujjwal Baid
- Center for AI and Data Science for Integrated Diagnostics (AI2D) I& Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Spyridon Bakas
- Center for AI and Data Science for Integrated Diagnostics (AI2D) I& Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | | | | | | | | |
Collapse
|
|
11
|
Raman F, Mullen A, Byrd M, Bae S, Kim J, Sotoudeh H, Morón FE, Fathallah-Shaykh HM. Evaluation of RANO Criteria for the Assessment of Tumor Progression for Lower-Grade Gliomas. Cancers (Basel) 2023; 15:3274. [PMID: 37444384 DOI: 10.3390/cancers15133274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 06/05/2023] [Accepted: 06/08/2023] [Indexed: 07/15/2023] Open
Abstract
PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for lower-grade gliomas (LGGs) define tumor progression as ≥25% change in the T2/FLAIR signal area based on an operator's discretion of the perpendicular diameter of the largest tumor cross-section. Potential sources of error include acquisition inconsistency of 2D slices, operator selection variabilities in both representative tumor cross-section and measurement line locations, and the inability to quantify infiltrative tumor margins and satellite lesions. Our goal was to assess the accuracy and reproducibility of RANO in LG. MATERIALS AND METHODS A total of 651 FLAIR MRIs from 63 participants with LGGs were retrospectively analyzed by three blinded attending physicians and three blinded resident trainees using RANO criteria, 2D visual assessment, and computer-assisted 3D volumetric assessment. RESULTS RANO product measurements had poor-to-moderate inter-operator reproducibility (r2 = 0.28-0.82; coefficient of variance (CV) = 44-110%; mean percent difference (diff) = 0.4-46.8%) and moderate-to-excellent intra-operator reproducibility (r2 = 0.71-0.88; CV = 31-58%; diff = 0.3-23.9%). When compared to 2D visual ground truth, the accuracy of RANO compared to previous and baseline scans was 66.7% and 65.1%, with an area under the ROC curve (AUC) of 0.67 and 0.66, respectively. When comparing to volumetric ground truth, the accuracy of RANO compared to previous and baseline scans was 21.0% and 56.5%, with an AUC of 0.39 and 0.55, respectively. The median time delay at diagnosis was greater for false negative cases than for false positive cases for the RANO assessment compared to previous (2.05 > 0.50 years, p = 0.003) and baseline scans (1.08 > 0.50 years, p = 0.02). CONCLUSION RANO-based assessment of LGGs has moderate reproducibility and poor accuracy when compared to either visual or volumetric ground truths.
Collapse
Affiliation(s)
- Fabio Raman
- Department of Radiology, Johns Hopkins Hospital, 600 N Wolfe St., Baltimore, MD 21287, USA
- Department of Radiology, The University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Alexander Mullen
- Department of Radiology, The University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Matthew Byrd
- Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Sejong Bae
- Department of Medicine, O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Jinsuh Kim
- Department of Radiology, Emory University, Atlanta, GA 30329, USA
| | - Houman Sotoudeh
- Department of Radiology, The University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Fanny E Morón
- Department of Radiology, Baylor College of Medicine, Houston, TX 77030, USA
| | | |
Collapse
|
|
12
|
Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. Int J Mol Sci 2023; 24:ijms24043151. [PMID: 36834563 PMCID: PMC9959624 DOI: 10.3390/ijms24043151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2023] [Revised: 01/29/2023] [Accepted: 02/02/2023] [Indexed: 02/09/2023] Open
Abstract
Immunotherapy constitutes a paradigm shift in cancer treatment. Its FDA approval for several indications has yielded improved prognosis for cases where traditional therapy has shown limited efficiency. However, many patients still fail to benefit from this treatment modality, and the exact mechanisms responsible for tumor response are unknown. Noninvasive treatment monitoring is crucial for longitudinal tumor characterization and the early detection of non-responders. While various medical imaging techniques can provide a morphological picture of the lesion and its surrounding tissue, a molecular-oriented imaging approach holds the key to unraveling biological effects that occur much earlier in the immunotherapy timeline. Magnetic resonance imaging (MRI) is a highly versatile imaging modality, where the image contrast can be tailored to emphasize a particular biophysical property of interest using advanced engineering of the imaging pipeline. In this review, recent advances in molecular-MRI based cancer immunotherapy monitoring are described. Next, the presentation of the underlying physics, computational, and biological features are complemented by a critical analysis of the results obtained in preclinical and clinical studies. Finally, emerging artificial intelligence (AI)-based strategies to further distill, quantify, and interpret the image-based molecular MRI information are discussed in terms of perspectives for the future.
Collapse
|
|
13
|
Sørensen PJ, Carlsen JF, Larsen VA, Andersen FL, Ladefoged CN, Nielsen MB, Poulsen HS, Hansen AE. Evaluation of the HD-GLIO Deep Learning Algorithm for Brain Tumour Segmentation on Postoperative MRI. Diagnostics (Basel) 2023; 13:diagnostics13030363. [PMID: 36766468 PMCID: PMC9914320 DOI: 10.3390/diagnostics13030363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 01/11/2023] [Accepted: 01/17/2023] [Indexed: 01/21/2023] Open
Abstract
In the context of brain tumour response assessment, deep learning-based three-dimensional (3D) tumour segmentation has shown potential to enter the routine radiological workflow. The purpose of the present study was to perform an external evaluation of a state-of-the-art deep learning 3D brain tumour segmentation algorithm (HD-GLIO) on an independent cohort of consecutive, post-operative patients. For 66 consecutive magnetic resonance imaging examinations, we compared delineations of contrast-enhancing (CE) tumour lesions and non-enhancing T2/FLAIR hyperintense abnormality (NE) lesions by the HD-GLIO algorithm and radiologists using Dice similarity coefficients (Dice). Volume agreement was assessed using concordance correlation coefficients (CCCs) and Bland-Altman plots. The algorithm performed very well regarding the segmentation of NE volumes (median Dice = 0.79) and CE tumour volumes larger than 1.0 cm3 (median Dice = 0.86). If considering all cases with CE tumour lesions, the performance dropped significantly (median Dice = 0.40). Volume agreement was excellent with CCCs of 0.997 (CE tumour volumes) and 0.922 (NE volumes). The findings have implications for the application of the HD-GLIO algorithm in the routine radiological workflow where small contrast-enhancing tumours will constitute a considerable share of the follow-up cases. Our study underlines that independent validations on clinical datasets are key to asserting the robustness of deep learning algorithms.
Collapse
Affiliation(s)
- Peter Jagd Sørensen
- Department of Radiology, Centre of Diagnostic Investigation, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, 2100 Copenhagen, Denmark
- The DCCC Brain Tumor Center, 2100 Copenhagen, Denmark
- Correspondence:
| | - Jonathan Frederik Carlsen
- Department of Radiology, Centre of Diagnostic Investigation, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Vibeke Andrée Larsen
- Department of Radiology, Centre of Diagnostic Investigation, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
| | - Flemming Littrup Andersen
- Department of Clinical Medicine, University of Copenhagen, 2100 Copenhagen, Denmark
- Department of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigation, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
| | - Claes Nøhr Ladefoged
- Department of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigation, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
| | - Michael Bachmann Nielsen
- Department of Radiology, Centre of Diagnostic Investigation, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Hans Skovgaard Poulsen
- The DCCC Brain Tumor Center, 2100 Copenhagen, Denmark
- Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
| | - Adam Espe Hansen
- Department of Radiology, Centre of Diagnostic Investigation, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, 2100 Copenhagen, Denmark
- The DCCC Brain Tumor Center, 2100 Copenhagen, Denmark
| |
Collapse
|
|
14
|
Hannisdal MH, Goplen D, Alam S, Haasz J, Oltedal L, Rahman MA, Rygh CB, Lie SA, Lundervold A, Chekenya M. Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI. Neurooncol Adv 2023; 5:vdad037. [PMID: 37152808 PMCID: PMC10162115 DOI: 10.1093/noajnl/vdad037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/09/2023] Open
Abstract
Background Tumor burden assessment is essential for radiation therapy (RT), treatment response evaluation, and clinical decision-making. However, manual tumor delineation remains laborious and challenging due to radiological complexity. The objective of this study was to investigate the feasibility of the HD-GLIO tool, an ensemble of pre-trained deep learning models based on the nnUNet-algorithm, for tumor segmentation, response prediction, and its potential for clinical deployment. Methods We analyzed the predicted contrast-enhanced (CE) and non-enhancing (NE) HD-GLIO output in 49 multi-parametric MRI examinations from 23 grade-4 glioma patients. The volumes were retrospectively compared to corresponding manual delineations by 2 independent operators, before prospectively testing the feasibility of clinical deployment of HD-GLIO-output to a RT setting. Results For CE, median Dice scores were 0.81 (95% CI 0.71-0.83) and 0.82 (95% CI 0.74-0.84) for operator-1 and operator-2, respectively. For NE, median Dice scores were 0.65 (95% CI 0.56-0,69) and 0.63 (95% CI 0.57-0.67), respectively. Comparing volume sizes, we found excellent intra-class correlation coefficients of 0.90 (P < .001) and 0.95 (P < .001), for CE, respectively, and 0.97 (P < .001) and 0.90 (P < .001), for NE, respectively. Moreover, there was a strong correlation between response assessment in Neuro-Oncology volumes and HD-GLIO-volumes (P < .001, Spearman's R2 = 0.83). Longitudinal growth relations between CE- and NE-volumes distinguished patients by clinical response: Pearson correlations of CE- and NE-volumes were 0.55 (P = .04) for responders, 0.91 (P > .01) for non-responders, and 0.80 (P = .05) for intermediate/mixed responders. Conclusions HD-GLIO was feasible for RT target delineation and MRI tumor volume assessment. CE/NE tumor-compartment growth correlation showed potential to predict clinical response to treatment.
Collapse
Affiliation(s)
- Marianne H Hannisdal
- Marianne H. Hannisdal, M.Sc., Department of Oncology, Haukeland University Hospital, Bergen Norway ()
| | - Dorota Goplen
- Department of Oncology, Haukeland University Hospital, BergenNorway
- University of Bergen, Bergen, Norway
| | - Saruar Alam
- Department of Radiology, Mohn Medical Imaging and Visualization Centre, Haukeland University Hospital, Bergen, Norway
- Department of Biomedicine
- University of Bergen, Bergen, Norway
| | - Judit Haasz
- Department of Radiology, Haukeland University Hospital, Bergen, Norway
- University of Bergen, Bergen, Norway
| | - Leif Oltedal
- Department of Radiology, Haukeland University Hospital, Bergen, Norway
- Department of Radiology, Mohn Medical Imaging and Visualization Centre, Haukeland University Hospital, Bergen, Norway
- University of Bergen, Bergen, Norway
| | - Mohummad A Rahman
- Department of Oncology, Haukeland University Hospital, BergenNorway
- Department of Biomedicine
- University of Bergen, Bergen, Norway
| | - Cecilie Brekke Rygh
- Department of Radiology, Haukeland University Hospital, Bergen, Norway
- University of Bergen, Bergen, Norway
| | - Stein Atle Lie
- Department of Clinical Odontology
- University of Bergen, Bergen, Norway
| | - Arvid Lundervold
- or Arvid Lundervold, MD, PhD, Department of Radiology, Mohn Medical Imaging and Visualization Centre, Haukeland University Hospital, Bergen, Norway ()
| | - Martha Chekenya
- Corresponding Author: Martha Chekenya, PhD, Department of Biomedicine, University of Bergen, Jonas Lies vei 91, 5020 Bergen, Norway ()
| |
Collapse
|
|
15
|
Ramakrishnan D, von Reppert M, Krycia M, Sala M, Mueller S, Aneja S, Nabavizadeh A, Galldiks N, Lohmann P, Raji C, Ikuta I, Memon F, Weinberg BD, Aboian MS. Evolution and implementation of radiographic response criteria in neuro-oncology. Neurooncol Adv 2023; 5:vdad118. [PMID: 37860269 PMCID: PMC10584081 DOI: 10.1093/noajnl/vdad118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2023] Open
Abstract
Radiographic response assessment in neuro-oncology is critical in clinical practice and trials. Conventional criteria, such as the MacDonald and response assessment in neuro-oncology (RANO) criteria, rely on bidimensional (2D) measurements of a single tumor cross-section. Although RANO criteria are established for response assessment in clinical trials, there is a critical need to address the complexity of brain tumor treatment response with multiple new approaches being proposed. These include volumetric analysis of tumor compartments, structured MRI reporting systems like the Brain Tumor Reporting and Data System, and standardized approaches to advanced imaging techniques to distinguish tumor response from treatment effects. In this review, we discuss the strengths and limitations of different neuro-oncology response criteria and summarize current research findings on the role of novel response methods in neuro-oncology clinical trials and practice.
Collapse
Affiliation(s)
- Divya Ramakrishnan
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Marc von Reppert
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Mark Krycia
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Matthew Sala
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
- Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Sabine Mueller
- Department of Neurology, Neurosurgery, and Pediatrics, University of California San Francisco, San Francisco, California, USA
| | - Sanjay Aneja
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Ali Nabavizadeh
- Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Norbert Galldiks
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany
- Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany
| | - Philipp Lohmann
- Institute of Neuroscience and Medicine (INM-4), Research Center Juelich, Juelich, Germany
| | - Cyrus Raji
- Department of Radiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
| | - Ichiro Ikuta
- Department of Radiology, Mayo Clinic, Phoenix, Arizona, USA
| | - Fatima Memon
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| | - Brent D Weinberg
- Department of Radiology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Mariam S Aboian
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA
| |
Collapse
|